Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
Development and validation of the Oxford Benchmark Scale for Rating Vaccine Technologies (OBSRVT), a scale for assessing public attitudes to next-generation vaccine delivery technologies.
Kantor J. et al, (2025), Human vaccines & immunotherapeutics, 21
Influential drivers of the cost-effectiveness of respiratory syncytial virus vaccination in European older adults: a multi-country analysis
Li X. et al, (2025), BMC Medicine, 23
Respiratory syncytial virus hospitalisation by chronological month of age and by birth month in infants
Guo L. et al, (2025), Nature Communications, 16
Dosing interval is a major factor determining the quality of T cells induced by SARS-CoV-2 mRNA and adenoviral vector vaccines
Murray SM. et al, (2025), Science Immunology, 10
Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil
Costa Clemens SA. et al, (2025), Mayo Clinic Proceedings Innovations Quality and Outcomes, 9
The waning of maternal measles antibodies: A multi-country maternal-infant seroprevalence study
Tiley KS. et al, (2025), Journal of Infection, 91, 106531 - 106531
Salmonella Typhi gut invasion drives hypoxic immune subsets associated with disease outcomes
Bossel Ben-Moshe N. et al, (2025), Nature Communications, 16
Age differences in immunity to human seasonal coronaviruses and the immunogenicity of ChAdOx1 nCoV-19 (AZD1222).
Belij-Rammerstorfer S. et al, (2025), EBioMedicine, 118
Prediction and characterisation of the human B cell response to a heterologous two-dose Ebola vaccine.
O'Connor D. et al, (2025), Nature communications, 16
Respiratory viral detection in children hospitalized with pneumonia during periods of major population disruptions in Nepal, 2014-2018.
Shrestha S. et al, (2025), Journal of the Pediatric Infectious Diseases Society
The TyphiNET data visualisation dashboard: unlocking Salmonella Typhi genomics data to support public health
Dyson ZA. et al, (2025), Genome Medicine, 17
A phase 1/2a clinical trial to assess safety and immunogenicity of an adenoviral-vectored capsular group B meningococcal vaccine
Dold C. et al, (2025), Science Translational Medicine, 17
Antibiotic use attributable to RSV infections during infancy-an international prospective birth cohort study.
Hak SF. et al, (2025), The Journal of antimicrobial chemotherapy
Consultation report - considerations for a regulatory pathway for bivalent Salmonella Typhi/Paratyphi A vaccines for use in endemic countries.
Ibarz-Pavon AB. et al, (2025), Vaccine, 56
Risk analysis for outpatient experimental infection as a pathway for affordable RSV vaccine development.
Siegal EZ. et al, (2025), NPJ vaccines, 10
Pneumococcal Carriage and Disease in Adults in England, 2011–2019: The Importance of Adults as a Reservoir for Pneumococcus in Communities
El Safadi D. et al, (2025), The Journal of Infectious Diseases, 231, e17 - e27
A 5-transcript signature for discriminating viral and bacterial etiology in pediatric pneumonia
Viz-Lasheras S. et al, (2025), iScience, 28, 111747 - 111747